Summary Alkylating agents can cause latent and permanent damage to the bone marrow. We compared the long term effects of melphalan on a number of immune and haemopoietic functions of plasmacytoma bearing BALB/c mice with that of normal mice treated with a similar dose of melphalan. The drug administered orally at a dose of 250,ug and 400 pg on day 14 and 24 following i.m. inoculation of MOPC-315 plasmacytoma cells resulted in cure of the mice. Their spleen cells showed a permanent impairment of MLR activity, T-cell number and IL-2 production as well as a mild suppression of NK activity for one year after cessation of melphalan therapy. The number of B cells was elevated. In contrast, plasmacytoma-free mice treated with melphalan retained long term normal immune functions, although shortly after melphalan therapy a temporary suppression was noted. On the other hand, melphalan was responsible for bone marrow myeloid stem cell damage since the number of myeloid progenitor cell (CFU-GM) colonies was reduced in both melphalan-treated groups compared to untreated normal controls. Plasmacytoma bearing mice had a shorter survival. These results demonstrate that some late sequelae of alkylating agents are not due to the drug alone; shorter survival and T-cell deficiency are related to the previous presence of the tumour.
Chemotherapeutic drugs often cause a temporary decline in blood cell production. With the increase in number of cancer patients who survive long periods after successful treatment, delayed and permanent bone marrow damage is being increasingly recognized (Harris, 1979; Testa et al., 1985; Greenberger et al., 1985; Schofield, 1986; Cuzick et al., 1987) . This may manifest clinically as low tolerance to subsequent chemotherapy (Testa et al., 1985) or as the development in some patients, after a clinically quiescent period, of severe marrow dysplasia with peripheral blood cytopenia which may progress to secondary acute nonlymphatic leukaemia (Harris, 1979; Levine & Bloomfield, 1987; Koeffler & Rowley, 1985) . Mice exposed to alkylating agents may develop permanent reduction of haemopoietic stem cell growth and self renewal despite an apparently normal blood and bone marrow cellularity (Morley et al., 1975; Botnick et al., 1978; Hays et al., 1982; Fried & Adler, 1985; Xu et al., 1986) . Such a latent marrow injury can later evolve into frank marrow failure or even transformation to leukaemia (Botnick et al., 1978; Morley & Blake, 1974) . Although late marrow damage is generally attributed to a mutagenic effect of the drugs on the haemopoietic stem cell(s) (Koeffler & Rowley, 1985; Sieber & Adamson, 1975) , the role of host factors has not been well studied.
Adaptive or natural immune effector mechanisms could mediate host surveillance against potentially malignant cells transformed by chemotherapy (Stutman, 1981) . A deficient or malfunctioning host immune defence could allow the expansion of transformed, premalignant cells (Stutman, 1981; Nowell, 1986) . However in patients cured of cancer by chemotherapy the analysis of the immune status is difficult to interpret. Late immune deficiency may not only reflect damage by the chemotherapeutic drugs, but also a late effect of the primary disease (Griffin et al., 1982; Milles & Cawley, 1983; Pilarski et al., 1985) .
In view of this uncertainty, we studied the long term effects of melphalan, on immune parameters of BALB/c mice cured of a transplanted plasmacytoma, in comparison to the drug's effects on mice without the tumour. Melphalan and plasmacytoma were chosen since patients with multiple myeloma are at a high risk for late myelodysplasia and acute leukaemia (Bergsagel & Pruzanski, 1985; Cuzick et al., 1987) . We focused on the immune profile during a period of one year after tumour eradication and off therapy. Concomitantly the in vitro growth of marrow myeloid progenitor cells was determined. This model enabled us to discriminate between long term damage to the immune and haemopoietic systems due to melphalan and injury related to the previous tumour burden.
Materials and methods

Tumour cells
Mineral oil-induced MOPC-315 plasmacytoma, (Potter & Walters, 1973; Ben-Efraim et al., 1983) treated by the same schedule of melphalan as group T + M (Group M). The mortality rates, at day 50, of melphalan treated mouse groups was similar: 6% for group M and 14% for group T+M.
For each experimental group -240 mice were used. They were followed for a period of 12 months. At monthly intervals, 15-24 mice which appeared to be well, were killed randomly from each group and spleen and femur bone marrow cells were obtained. The immune profile and in vitro myeloid colony growth were studied. For the final analysis all values of individual mice at each point in time were pooled and the mean calculated. The significance of the differences between the groups was tested by the Student's t test. All mice were dissected and found free of tumour. Mixed lymphocyte reaction Spleen cells were prepared for mixed lymphocytic reaction (MLR) as previously described (Peck & Bach, 1973) . Briefly, mitogen stimulated cells obtained from C3HeB or BALB/c mice were incubated with responder cells from the BALB/c mice at a ratio of 1:1.5 in RPMI-1640 medium and 2.5% FCS. Three days later the cells were labelled with 3H-thymidine. The net stimulation was calculated by subtracting cpm of syngeneic mixed lymphocyte culture from cpm of allogeneic culture. cpm in experimental wells -% lysis = cpm released spontaneously total cpm incorporatedcpm released spontaneously Spontaneous release was 10-30%.
Antibodies
Interleukin-2 (IL-2) production The IL-2 assay has been described previously (Gillis et al., 1978) . Briefly, spleen cells (8 x I0O cells ml-) were cultured with 2.5jpgml-1 of ConA (Bio Yeda, Rehovot, Israel) for 48 h. IL-2 production was measured by adding the supernatants (0.1 ml) to ConA induced blasts (1 x 105cells ml -1) cultured in RPMI-1640 medium containing 10% FCS, and 5 x 10-5 M 2-mercaptoethanol and labelled with 3H-thymidine. IL-2 units were calculated with the aid of a standard IL-2 preparation.
CFU-GM colony assay Bone marrow cells, 105 in 1 ml alpha medium (Flow Laboratories, Irvine, UK), 15% FCS, 0.3% bacto agar and 10% mouse lung conditioned medium as a source of colony stimulating activity, were placed in 35mm petri dishes. After incubation in a humidified incubator with 5% CO2 at 37°C for 7 days, myeloid-macrophage progenitor cell (CFU-GM) colonies (>20 cells) were scored.
Results
Survival
Late survival of the mouse groups was compared by life table analysis (Kaplan & Meier, 1957) (Figure 1 ). During the follow-up period of one year, the melphalan-treated plasmacytoma-bearing mice showed a higher mortality rate than the group of normal mice treated by equivalent doses of this drug. No evidence of residual plasmacytoma was found in any dissected mouse of group T + M.
T-cellfunction and number
The ability of splenic cells from M, T + M and C mouse groups to respond to alloantigens expressed on C3HeB splenocytes in MLR is depicted in Figure 2 activity recovered spontaneously and remained normal throughout the experiment. In contrast to the spontaneous recovery in group M, the MLR in group T+M remained below normal for one year (P<0.05 as compared to group C or group M). Splenic T-cell numbers measured by monoclonal anti Thyl.2 antibodies are shown in Figure 3 . In group M, melphalan reduced the number of Thyl.2 positive cells but by day 60 they recovered and reached normal levels. In group T + M, up to day 60 and after day 120, the impaired T-cell function was associated with a significant reduction of Thyl.2 positive cells compared to group C and group M (P<0.05). Only during a short period (days 60-90) could the reduced MLR in groups M and T+M not be accounted for by decreased Thyl.2 positive cells. Throughout the entire study period production of IL-2 by splenic cells of group T + M was significantly lower than group M and C (P<0.05) (Figure 4 ). Though the difference appears rather small it was consistent at all points in time.
NK cell activity and number NK activity of splenic cells is shown in Figure 5 . A wide range of levels was found in untreated control mice (group C). After 210 days of observation NK activity declined, presumably due to aging of the mice. Melphalan treatment of normal mice (group M) markedly suppressed NK activity, recovering to normal after day 90. The NK activity in group T+M did not decline until day 60 after treatment. During days 60-240 the NK activity in group T+M was lower than in normal untreated mice (P < 0.05). In general, the differences in NK activity between the three mouse groups were minimal. Figure 6 demonstrates that in both treated groups (M and T + M) the number of NK (asialo GM1 positive) cells was initially markedly reduced, rollowed by a spontaneous recovery by -day 80, and no further decline during the rest of the study period. GM colonies was persistently low (group M and T + M) compared t (P < 0.05) (Figure 8 ). During thir peripheral blood erythrocytes, leul not differ between untreated and shown).
to Figure 2) . In untreated declined, These parameters recovered spontaneously by 3-4 were positive.(I = group months after treatment and remained within the normal range. These results confirm previous studies in normal mice showing that an intensive course of melphalan causes a transient cellular immune damage (Harris et al., 1976; Makinodan et al., 1970; Ehrlich et al., 1983 This is an interesting observation, since an increased marrow B and pre B cell compartment was also found in patients with acute lymphocytic leukaemia, lymphoma and solid tumours in remission for more than 2 years after cessation of therapy (Paolucci et al., 1979; Pearl, 1983) .
Previous studies in normal mice demonstrated that the alkylating agents, melphalan and busulphan, produce permanent injury to the proliferative capacity of the marrow haemopoietic stem cells. Decreased marrow CFU-S and CFU-GM pools (Morley et al., 1975; Hays et al., 1982; Fried & Adler, 1985) and CFU-S self renewal capacity (Botnick et al., 1978) was evident even 2 years after termination therapy. The present results show that one of the haemopoietic precursors, i.e., the growth of CFU-GM colonies, is permanently suppressed by melphalan but in contrast to T-cell number and function, its suppression is independent of the presence of a previous tumour. Morley and Blake (1974) have reported that normal mice surviving the acute toxicity of busulphan administration show a high rate of late deaths. The mice died from marrow failure with blood cytopenia or from leukaemia, after a period of a latent bone marrow injury. In the present study, the administration of melphalan for a short period resulted in a slightly reduced survival. Plasmacytoma-bearing mice cured by the same dose of melphalan had an even greater mortality rate, the cause of which could not be established in the present study. Though, in no instance, could we find plasmacytoma recurrence investigations are needed to determine if the excess mortality in group T+M was due to marrow failure, to infections related to the immune deficiency or to other causes. Previous reports on release of viruses by MOPC-3 15 plasmacytoma cells may have relevance in explaining this observation (Schwarzbard et al., 1985) . However our data support the notion that in animals cured of plasmacytoma, the late sequelae are not due to the drugs alone; survival and immune functions may be modified by the presence of factors related to the cancer in the past.
Clinical experience suggests that myelodysplasia and secondary acute leukaemia occur more frequently in multiple myeloma than in other categories of cancer patients receiving similar drugs (Bergsagel & Pruzanski, 1985; Fisher et al., 1985) . Whether in our model, the immune deficiency in melphalan-treated plasmacytoma-bearing mice will lead to more leukaemias than in melphalan treated normal mice, remains to be established.
